A Phase 1/2 Trial of MG1 Maraba Expressing MAGE-A3 (MG1-MAGEA3), With Adenovirus Vaccine Expressing MAGE-A3 (Ad-MAGEA3), in Combination With Pembrolizumab in Patients With Previously Treated Metastatic Non-Small Cell Lung Cancer (NSCLC)
Phase of Trial: Phase I/II
Latest Information Update: 07 Sep 2017
At a glance
- Drugs MG1 MA3 (Primary) ; Pembrolizumab
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms Sandpiper Trial
- Sponsors Turnstone Biologics
- 01 Sep 2017 Planned number of patients changed from 55 to 61.
- 01 Sep 2017 Planned End Date changed from 1 Nov 2020 to 1 Aug 2021.
- 01 Sep 2017 Planned primary completion date changed from 1 Jan 2018 to 1 Jan 2020.